Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
–Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million
Company newsroom
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
1 releases